An Observational, Multicenter, Open-label Study of YONDELIS + PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Trabectedin (Primary) ; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions
- Acronyms NIS-OvaYond
- Sponsors PharmaMar
- 07 Jun 2017 Biomarkers information updated
- 13 Apr 2017 Status changed from active, no longer recruiting to completed.
- 24 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.